With Aduhelm in tat­ters, the search is on for Michel Vounatsos' re­place­ment at Bio­gen; David Liu, Roger Perl­mut­ter join in­sitro's SAB

→ Be­cause of the dearth of Alzheimer’s treat­ments, Bio­gen pushed ag­gres­sive­ly to cross the reg­u­la­to­ry goal line with ad­u­canum­ab de­spite ear­ly tri­al wrap-ups and per­va­sive ef­fi­ca­cy ques­tions. The high­ly con­tro­ver­sial ap­proval of Aduhelm, and the calami­tous roll­out that fol­lowed, proved to be the un­do­ing of CEO Michel Vounatsos, who was hired from with­in to re­place George Scan­gos on Jan. 6, 2017. Dis­cus­sions in the in­dus­try should be live­ly over who gets the job next at Bio­gen as Vounatsos will re­tain his po­si­tion un­til the com­pa­ny finds a suc­ces­sor, which will be no lat­er than Feb. 28, 2023.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.